About the CEO

Dr. Thomas R. Caulfield is the Founder and Chief Executive Officer of Digital Ether Computing, where he is pioneering new architectures of artificial intelligence to transform drug discovery, functional genomics, and the future of molecular medicine. His vision is to create adaptive intelligence systems that not only accelerate the development of therapies but also redefine how knowledge itself is structured and applied to human health.

Under his leadership, Digital Ether Computing has introduced breakthrough platforms that embody this mission: Liquid Adaptive AI, a continuously adaptive reasoning system designed to learn in real time; the Dynamicasome, a genomic atlas capturing the structural and functional consequences of every missense mutation; LC-JT-VAE, a generative molecular design engine that produces highly accurate drug candidates; and Nexomorphs, a first-in-class category of therapeutics capable of reprogramming disease biology. Together, these technologies position the company at the frontier of AI, biology, and medicine.

Dr. Caulfield brings to this role a distinguished scientific career. As Director of the Drug Discovery, Design and Optimization Laboratory at Mayo Clinic, he led programs for more than a decade that generated over 65 patents, authored 110+ peer-reviewed publications, and advanced multiple compounds into Phase I clinical trials. His discoveries have been translated into collaborations with global pharmaceutical companies and have been featured in leading journals, including Nature Communications Biology, Science Advances, Biomolecules, and AI.

He holds a B.S. in Physics (Mathematics), an M.S. in Chemistry, and a Ph.D. in Chemistry/Biophysics from Georgia Tech, with postdoctoral research at Roche, UC San Diego, and TPIMS, followed by a fellowship at Mayo Clinic.

Driven by a personal mission to apply AI as a transformative force for humanity, Dr. Caulfield is building Digital Ether Computing into a company that redefines the boundaries of medicine while laying the foundations for adaptive intelligence across society.

Ryan King, CMC (Ret.), is the Chief Operating Officer of Digital Ether Computing, where he oversees operational strategy, partnerships, and execution of the company’s AI-driven drug discovery programs. A retired Navy officer with more than 25 years of leadership experience, Ryan brings deep expertise in managing complex organizations and delivering mission-critical results.

As COO, he drives the alignment of Digital Ether Computing’s scientific innovations with business operations, ensuring the company’s breakthrough platforms, including Liquid Adaptive AI, the Dynamicasome, and LC-JT-VAE, are positioned for real-world translation. His leadership supports investor relations, strategic collaborations, and the scaling of operations from research into therapeutic pipelines.

Ryan’s Navy career included roles in command, logistics, and operational planning, where he earned a reputation for disciplined execution and organizational excellence. He has successfully transitioned these skills to the biotech and AI sector, helping Digital Ether Computing establish key industry and academic partnerships while navigating the fast-moving startup landscape.

With his combination of military precision and entrepreneurial drive, Ryan ensures the company’s vision of transforming medicine through adaptive AI is backed by sound operational and financial strategy.

Naeyma Islam, PhD, is the Chief Technology Officer of Digital Ether Computing, where she builds the AI architectures and computational infrastructure that turn molecular data into designed medicines. Her work sits at the convergence of generativeAI, molecular simulation, and structure-based drug design, and is guided by a single conviction: that computation should not merely predict biology, but design against it.

 At Digital Ether Computing she leads the technology stack behind the company's discovery platforms, GPU-scale simulation infrastructure, generative chemistry engines that produce synthesizable, target-conditioned molecules, and multi-modal predictive models that fuse chemical structure with cell-based phenotypic data. She has developed AI systems that couple molecular dynamics with machine learning to resolve the functional consequences of genetic variation, generative models for targeted protein degradation, and predictive frameworks for absorption, distribution, metabolism, excretion, and toxicity. She is also a co-architect of the company's continuously adaptive reasoning framework, the theoretical foundation for its next generation of self-improving intelligence systems.

 With extensive experience in molecular pharmacology, assay development, and drug discovery, Naeyma bridges the gap between Digital Ether Computing’s adaptive AI platforms and their application to real-world pipelines/applications. She was involved in the development of the Dynamicasome, LC-JT-VAE, and Liquid Adaptive AI.   She also has past experience across oncology (cancers), neurology (neurodegeneration), and other disease areas (eg. cardiology, reproductive disorders (endometriosis), kidney disease).

 Before joining Digital Ether Computing, Dr. Islam was Assistant Professor in the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic, where she worked on several computational programs across oncology and neurodegeneration: enzyme and metabolite-driven mechanisms in liver cancer, protein–protein interaction inhibition, aptamer therapeutics, and AI-driven property prediction, alongside structural work on several neurodegenerative disease.

Alex Baker, PhD, is a PI in the Therapeutics Discovery Division at Digital Ether Computing, where he leads projects for translational drug research programs. With extensive experience in molecular pharmacology, assay development, and drug discovery, Alex bridges over Digital Ether Computing’s adaptive AI platform to the therapeutic pipelines. He heads the validation of compounds generated by Liquid Adaptive AI, the Dynamicasome, and LC-JT-VAE, ensuring that discoveries are rigorously tested and advanced toward preclinical and clinical milestones. His leadership strengthens the company’s ability to turn AI-driven models into tangible therapies that address urgent unmet medical needs.

 Alex’s career spans both academic and industry settings, where he has established a reputation for building innovative platforms that connect computational discovery with experimental validation. He has developed assays for molecular glues, targeted protein degradation, and next-generation therapeutics, providing critical expertise to accelerate Digital Ether Computing’s research and development.

 By combining scientific rigor with an entrepreneurial mindset, Alex ensures that the company’s vision of transforming medicine with adaptive AI is anchored in strong experimental evidence and positioned for impact across oncology, neurology, and other major disease areas.